Is Ofatumumab included in medical insurance?

Ofatumumab (Ofatumumab) was approved by the National Medical Products Administration in in 2021 for the treatment of adult relapsing Multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis, is a relatively rare disease that has subsequently entered the scope of Class B medical insurance, but is limited to reimbursement for adult relapsing multiple sclerosis (RMS).

Ofatumumab is a fully human anti-CD20 monoclonal antibody whose epitope is different from that of rituximab. Ofatumumabbinds to a unique epitope on the large and small extracellular loops of CD20, an antigen expressed only on B-cell lymphocytes. Compared with rituximab, ofatumumab binds more tightly to CD20 and has a lower shedding rate. It causes cytotoxicity in CD20-expressing cells via complement-dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC).

The brand name of the original drug of ofatumumab in the domestic market is Quanxinda, and its price may be around tens of thousands of yuan. Domestic purchase channels are relatively difficult, and the reimbursement ratios are different in different regions. The price after reimbursement may be different. For specific prices, you can ask the local medical insurance bureau and other places. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.